Identification of PAthways of Kinase Inhibitors TOxicity (PAKITO)

Groupe Hospitalier Pitie-Salpetriere

Status: Completed

Conditions: Kinase Inhibitors Toxicity

Treatments: Drug: Kinase inhibitor

Study type: Observational

Funder types: Other

Identifiers

NCT03896139

CIC1421-1906

Details and patient eligibility

About

The investigators are identifying clinical diagnoses and toxicities associated with kinase inhibitors prescription. This identification will be applied will be applied in an electronic-health-record (EHR) cohort including North American and European.

Enrollment: 4,000 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patient treated with a kinase inhibitor
• Patient identified in the VUMC EHR cohort or having a toxicity reported in the VigiBase

Exclusion criteria

Trial design

4,000 participants in 2 patient groups

VUMC EHR cohort

Description:

De-identified version of the electronic health record (EHR) at Vanderbilt University Medical Center (VUMC).

Treatment:

Drug: Kinase inhibitor

Toxicity induced by kinase inhibitors in Vigibase database

Description:

Case reported in the World Health Organization (WHO) of toxicity or complication of patient treated by KIs, with a chronology compatible with the drug toxicity

Treatment:

Drug: Kinase inhibitor